

## **Quadracel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine)**

Quadracel® is indicated for active immunization against diphtheria, tetanus, pertussis, and poliomyelitis. A single dose of Quadracel® is approved as a fifth dose in the diphtheria, tetanus, pertussis (DTaP) vaccination series, and as a fourth or fifth dose in the inactivated poliovirus (IPV) vaccination series, in children 4 through 6 years of age whose previous DTaP vaccine doses have been with Pentacel® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus and Haemophilus b Conjugate [Tetanus Toxoid Conjugate] Vaccine) and/or DAPTACEL® (Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed) and/or VAXELIS® (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine).

### **IMPORTANT SAFETY INFORMATION FOR QUADRACEL®**

Contraindications to vaccination with Quadracel® include: a severe allergic reaction (e.g., anaphylaxis) to any ingredient of Quadracel® or following any other diphtheria toxoid-, tetanus toxoid-, or pertussis antigen-containing vaccine, or inactivated poliovirus vaccine; encephalopathy within 7 days of a previous dose of a pertussis antigen-containing vaccine that is not attributable to another identifiable cause; or a progressive neurologic disorder.

Carefully consider benefits and risks before administering Quadracel® to persons with a history of: fever  $\geq 105^{\circ}\text{F}$ , hypotonic-hyporesponsive episode, or persistent, inconsolable crying lasting  $\geq 3$  hours within 48 hours after a previous pertussis antigen-containing vaccine; seizures within 3 days after a previous pertussis antigen-containing vaccine; Guillain-Barré syndrome occurring within 6 weeks of receipt of a prior vaccine containing tetanus toxoid; or adverse events after a previous dose of Quadracel® or receipt of any other tetanus toxoid-, diphtheria toxoid-, or pertussis antigen-containing vaccine.

Syncope (fainting) may occur in association with administration of injectable vaccines including Quadracel®. Procedures should be in place to avoid injury from fainting.

The most common local and systemic adverse reactions to Quadracel® include pain, erythema, and edema at the injection site; myalgia, malaise, and headache. Other adverse reactions may occur.

Vaccination with Quadracel® may not protect all individuals.

Please see full Prescribing Information for Quadracel ([49281-564-10](#) and [49281-562-10](#))